Market Analysis and Insights: Global Everolimus Drug Market
Due to the COVID-19 pandemic, the global Everolimus Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 2.5mg Tables accounting for % of the Everolimus Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Kidney Cancer segment is altered to an % CAGR throughout this forecast period.
China Everolimus Drug market size is valued at US$ million in 2021, while the US and Europe Everolimus Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Everolimus Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Everolimus Drug include Novartis, Glenmark Pharmaceuticals, Cipla, Dr Reddy's Laboratories, Natco Pharma, Intas Pharmaceuticals, Panacea Biotec, Alkem Laboratories and Biocon Pharma. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Everolimus Drug Scope and Segment
Everolimus Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Everolimus Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- 2.5mg Tables
- 5mg Tables
- 10mg Tables
- Dispersible Tablet
Segment by Application
- Kidney Cancer
- Immune Rejection of Organ Transplantation
- Subependymal Giant Cell Astrocytoma (SEGA)
- Pancreatic Neuroendocrine Tumors
- Breast Cancer
- Tuberous Sclerosis Complex-associated Partial-onset Seizures
- Other
By Company
- Novartis
- Glenmark Pharmaceuticals
- Cipla
- Dr Reddy's Laboratories
- Natco Pharma
- Intas Pharmaceuticals
- Panacea Biotec
- Alkem Laboratories
- Biocon Pharma
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
TABLE OF CONTENTS
1 Study Coverage
- 1.1 Everolimus Drug Product Introduction
- 1.2 Market by Type
- 1.2.1 Global Everolimus Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 2.5mg Tables
- 1.2.3 5mg Tables
- 1.2.4 10mg Tables
- 1.2.5 Dispersible Tablet
- 1.3 Market by Application
- 1.3.1 Global Everolimus Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Kidney Cancer
- 1.3.3 Immune Rejection of Organ Transplantation
- 1.3.4 Subependymal Giant Cell Astrocytoma (SEGA)
- 1.3.5 Pancreatic Neuroendocrine Tumors
- 1.3.6 Breast Cancer
- 1.3.7 Tuberous Sclerosis Complex-associated Partial-onset Seizures
- 1.3.8 Other
- 1.4 Study Objectives
- 1.5 Years Considered
2 Executive Summary
- 2.1 Global Everolimus Drug Sales Estimates and Forecasts 2017-2028
- 2.2 Global Everolimus Drug Revenue Estimates and Forecasts 2017-2028
- 2.3 Global Everolimus Drug Revenue by Region: 2017 VS 2021 VS 2028
- 2.4 Global Everolimus Drug Sales by Region
- 2.4.1 Global Everolimus Drug Sales by Region (2017-2022)
- 2.4.2 Global Sales Everolimus Drug by Region (2023-2028)
- 2.5 Global Everolimus Drug Revenue by Region
- 2.5.1 Global Everolimus Drug Revenue by Region (2017-2022)
- 2.5.2 Global Everolimus Drug Revenue by Region (2023-2028)
- 2.6 North America
- 2.7 Europe
- 2.8 Asia-Pacific
- 2.9 Latin America
- 2.10 Middle East & Africa
3 Competition by Manufacturers
- 3.1 Global Everolimus Drug Sales by Manufacturers
- 3.1.1 Global Top Everolimus Drug Manufacturers by Sales (2017-2022)
- 3.1.2 Global Everolimus Drug Sales Market Share by Manufacturers (2017-2022)
- 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Everolimus Drug in 2021
- 3.2 Global Everolimus Drug Revenue by Manufacturers
- 3.2.1 Global Everolimus Drug Revenue by Manufacturers (2017-2022)
- 3.2.2 Global Everolimus Drug Revenue Market Share by Manufacturers (2017-2022)
- 3.2.3 Global Top 10 and Top 5 Companies by Everolimus Drug Revenue in 2021
- 3.3 Global Everolimus Drug Sales Price by Manufacturers (2017-2022)
- 3.4 Analysis of Competitive Landscape
- 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Everolimus Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4.3 Global Everolimus Drug Manufacturers Geographical Distribution
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Global Everolimus Drug Sales by Type
- 4.1.1 Global Everolimus Drug Historical Sales by Type (2017-2022)
- 4.1.2 Global Everolimus Drug Forecasted Sales by Type (2023-2028)
- 4.1.3 Global Everolimus Drug Sales Market Share by Type (2017-2028)
- 4.2 Global Everolimus Drug Revenue by Type
- 4.2.1 Global Everolimus Drug Historical Revenue by Type (2017-2022)
- 4.2.2 Global Everolimus Drug Forecasted Revenue by Type (2023-2028)
- 4.2.3 Global Everolimus Drug Revenue Market Share by Type (2017-2028)
- 4.3 Global Everolimus Drug Price by Type
- 4.3.1 Global Everolimus Drug Price by Type (2017-2022)
- 4.3.2 Global Everolimus Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
- 5.1 Global Everolimus Drug Sales by Application
- 5.1.1 Global Everolimus Drug Historical Sales by Application (2017-2022)
- 5.1.2 Global Everolimus Drug Forecasted Sales by Application (2023-2028)
- 5.1.3 Global Everolimus Drug Sales Market Share by Application (2017-2028)
- 5.2 Global Everolimus Drug Revenue by Application
- 5.2.1 Global Everolimus Drug Historical Revenue by Application (2017-2022)
- 5.2.2 Global Everolimus Drug Forecasted Revenue by Application (2023-2028)
- 5.2.3 Global Everolimus Drug Revenue Market Share by Application (2017-2028)
- 5.3 Global Everolimus Drug Price by Application
- 5.3.1 Global Everolimus Drug Price by Application (2017-2022)
- 5.3.2 Global Everolimus Drug Price Forecast by Application (2023-2028)
6 North America
- 6.1 North America Everolimus Drug Market Size by Type
- 6.1.1 North America Everolimus Drug Sales by Type (2017-2028)
- 6.1.2 North America Everolimus Drug Revenue by Type (2017-2028)
- 6.2 North America Everolimus Drug Market Size by Application
- 6.2.1 North America Everolimus Drug Sales by Application (2017-2028)
- 6.2.2 North America Everolimus Drug Revenue by Application (2017-2028)
- 6.3 North America Everolimus Drug Market Size by Country
- 6.3.1 North America Everolimus Drug Sales by Country (2017-2028)
- 6.3.2 North America Everolimus Drug Revenue by Country (2017-2028)
- 6.3.3 U.S.
- 6.3.4 Canada
7 Europe
- 7.1 Europe Everolimus Drug Market Size by Type
- 7.1.1 Europe Everolimus Drug Sales by Type (2017-2028)
- 7.1.2 Europe Everolimus Drug Revenue by Type (2017-2028)
- 7.2 Europe Everolimus Drug Market Size by Application
- 7.2.1 Europe Everolimus Drug Sales by Application (2017-2028)
- 7.2.2 Europe Everolimus Drug Revenue by Application (2017-2028)
- 7.3 Europe Everolimus Drug Market Size by Country
- 7.3.1 Europe Everolimus Drug Sales by Country (2017-2028)
- 7.3.2 Europe Everolimus Drug Revenue by Country (2017-2028)
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 U.K.
- 7.3.6 Italy
- 7.3.7 Russia
8 Asia Pacific
- 8.1 Asia Pacific Everolimus Drug Market Size by Type
- 8.1.1 Asia Pacific Everolimus Drug Sales by Type (2017-2028)
- 8.1.2 Asia Pacific Everolimus Drug Revenue by Type (2017-2028)
- 8.2 Asia Pacific Everolimus Drug Market Size by Application
- 8.2.1 Asia Pacific Everolimus Drug Sales by Application (2017-2028)
- 8.2.2 Asia Pacific Everolimus Drug Revenue by Application (2017-2028)
- 8.3 Asia Pacific Everolimus Drug Market Size by Region
- 8.3.1 Asia Pacific Everolimus Drug Sales by Region (2017-2028)
- 8.3.2 Asia Pacific Everolimus Drug Revenue by Region (2017-2028)
- 8.3.3 China
- 8.3.4 Japan
- 8.3.5 South Korea
- 8.3.6 India
- 8.3.7 Australia
- 8.3.8 Taiwan
- 8.3.9 Indonesia
- 8.3.10 Thailand
- 8.3.11 Malaysia
- 8.3.12 Philippines
9 Latin America
- 9.1 Latin America Everolimus Drug Market Size by Type
- 9.1.1 Latin America Everolimus Drug Sales by Type (2017-2028)
- 9.1.2 Latin America Everolimus Drug Revenue by Type (2017-2028)
- 9.2 Latin America Everolimus Drug Market Size by Application
- 9.2.1 Latin America Everolimus Drug Sales by Application (2017-2028)
- 9.2.2 Latin America Everolimus Drug Revenue by Application (2017-2028)
- 9.3 Latin America Everolimus Drug Market Size by Country
- 9.3.1 Latin America Everolimus Drug Sales by Country (2017-2028)
- 9.3.2 Latin America Everolimus Drug Revenue by Country (2017-2028)
- 9.3.3 Mexico
- 9.3.4 Brazil
- 9.3.5 Argentina
10 Middle East and Africa
- 10.1 Middle East and Africa Everolimus Drug Market Size by Type
- 10.1.1 Middle East and Africa Everolimus Drug Sales by Type (2017-2028)
- 10.1.2 Middle East and Africa Everolimus Drug Revenue by Type (2017-2028)
- 10.2 Middle East and Africa Everolimus Drug Market Size by Application
- 10.2.1 Middle East and Africa Everolimus Drug Sales by Application (2017-2028)
- 10.2.2 Middle East and Africa Everolimus Drug Revenue by Application (2017-2028)
- 10.3 Middle East and Africa Everolimus Drug Market Size by Country
- 10.3.1 Middle East and Africa Everolimus Drug Sales by Country (2017-2028)
- 10.3.2 Middle East and Africa Everolimus Drug Revenue by Country (2017-2028)
- 10.3.3 Turkey
- 10.3.4 Saudi Arabia
11 Company Profiles
- 11.1 Novartis
- 11.1.1 Novartis Corporation Information
- 11.1.2 Novartis Overview
- 11.1.3 Novartis Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.1.4 Novartis Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.1.5 Novartis Recent Developments
- 11.2 Glenmark Pharmaceuticals
- 11.2.1 Glenmark Pharmaceuticals Corporation Information
- 11.2.2 Glenmark Pharmaceuticals Overview
- 11.2.3 Glenmark Pharmaceuticals Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.2.4 Glenmark Pharmaceuticals Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.2.5 Glenmark Pharmaceuticals Recent Developments
- 11.3 Cipla
- 11.3.1 Cipla Corporation Information
- 11.3.2 Cipla Overview
- 11.3.3 Cipla Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.3.4 Cipla Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.3.5 Cipla Recent Developments
- 11.4 Dr Reddy's Laboratories
- 11.4.1 Dr Reddy's Laboratories Corporation Information
- 11.4.2 Dr Reddy's Laboratories Overview
- 11.4.3 Dr Reddy's Laboratories Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.4.4 Dr Reddy's Laboratories Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.4.5 Dr Reddy's Laboratories Recent Developments
- 11.5 Natco Pharma
- 11.5.1 Natco Pharma Corporation Information
- 11.5.2 Natco Pharma Overview
- 11.5.3 Natco Pharma Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.5.4 Natco Pharma Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.5.5 Natco Pharma Recent Developments
- 11.6 Intas Pharmaceuticals
- 11.6.1 Intas Pharmaceuticals Corporation Information
- 11.6.2 Intas Pharmaceuticals Overview
- 11.6.3 Intas Pharmaceuticals Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.6.4 Intas Pharmaceuticals Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.6.5 Intas Pharmaceuticals Recent Developments
- 11.7 Panacea Biotec
- 11.7.1 Panacea Biotec Corporation Information
- 11.7.2 Panacea Biotec Overview
- 11.7.3 Panacea Biotec Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.7.4 Panacea Biotec Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.7.5 Panacea Biotec Recent Developments
- 11.8 Alkem Laboratories
- 11.8.1 Alkem Laboratories Corporation Information
- 11.8.2 Alkem Laboratories Overview
- 11.8.3 Alkem Laboratories Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.8.4 Alkem Laboratories Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.8.5 Alkem Laboratories Recent Developments
- 11.9 Biocon Pharma
- 11.9.1 Biocon Pharma Corporation Information
- 11.9.2 Biocon Pharma Overview
- 11.9.3 Biocon Pharma Everolimus Drug Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.9.4 Biocon Pharma Everolimus Drug Product Model Numbers, Pictures, Descriptions and Specifications
- 11.9.5 Biocon Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
- 12.1 Everolimus Drug Industry Chain Analysis
- 12.2 Everolimus Drug Key Raw Materials
- 12.2.1 Key Raw Materials
- 12.2.2 Raw Materials Key Suppliers
- 12.3 Everolimus Drug Production Mode & Process
- 12.4 Everolimus Drug Sales and Marketing
- 12.4.1 Everolimus Drug Sales Channels
- 12.4.2 Everolimus Drug Distributors
- 12.5 Everolimus Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
- 13.1 Everolimus Drug Industry Trends
- 13.2 Everolimus Drug Market Drivers
- 13.3 Everolimus Drug Market Challenges
- 13.4 Everolimus Drug Market Restraints
14 Key Findings in The Global Everolimus Drug Study
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.2 Data Source
- 15.2 Author Details
- 15.3 Disclaimer